| Literature DB >> 30248906 |
Elizabeth A Pusch1, David L Suarez2.
Abstract
Poultry-adapted H9N2 avian influenza viruses (AIVs) are commonly found in many countries in Asia, the Middle East, Africa, and Europe, and although classified as low pathogenic viruses, they are an economically important disease. Besides the importance of the disease in the poultry industry, some H9N2 AIVs are also known to be zoonotic. The disease in humans appears to cause primarily a mild upper respiratory disease, and doesn't cause or only rarely causes the severe pneumonia often seen with other zoonotic AIVs like H5N1 or H7N9. Serologic studies in humans, particularly in occupationally exposed workers, show a large number of people with antibodies to H9N2, suggesting infection is commonly occurring. Of the four defined H9N2 poultry lineages, only two lineages, the G1 and the Y280 lineages, are associated with human infections. Almost all of the viruses from humans have a leucine at position 226 (H3 numbering) of the hemagglutinin associated with a higher affinity of binding with α2,6 sialic acid, the host cell receptor most commonly found on glycoproteins in the human upper respiratory tract. For unknown reasons there has also been a shift in recent years of poultry viruses in the G1 and Y280 lineages to also having leucine instead of glutamine, the amino acid found in most avian viruses, at position 226. The G1 and Y280 poultry lineages because of their known ability to infect humans, the high prevalence of the virus in poultry in endemic countries, the lack of antibody in most humans, and the shift of poultry viruses to more human-like receptor binding makes these viruses a human pandemic threat. Increased efforts for control of the virus, including through effective vaccine use in poultry, is warranted for both poultry and public health goals.Entities:
Keywords: H9N2; avian influenza; human infection; zoonotic
Year: 2018 PMID: 30248906 PMCID: PMC6313933 DOI: 10.3390/vetsci5040082
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Comparison of amino acid variation at position 226 (H3 numbering) of H9N2 isolates from different geographic regions.
| Origin | Glutamine | Leucine | Total Isolates |
|---|---|---|---|
| North America 1966–2017 a | 100% b | 0% | 68 |
| South Korea 1996–2012 | 100% | 0% | 128 |
| China 1980–1997 | 59.50% | 40.50% | 42 |
| China 1998–2000 | 39.80% | 60.10% | 153 |
| China 2001–2003 | 25.70% | 74.30% | 268 |
| China 2004–2006 | 26.70% | 73.30% | 236 |
| China 2007–2009 | 14.20% | 85.80% | 513 |
| China 2010–2012 | 6.90% | 93.10% | 1182 |
| China 2013–2015 | 2.80% | 97.20% | 688 |
| China 2016-2018 | 3.00% | 97.00% | 66 |
| rest of world 1980–2000 | 61.10% | 38.90% | 90 |
| rest of world 2001–2003 | 32% | 68% | 147 |
| rest of world 2004–2006 | 32% | 68% | 128 |
| rest of world 2007–2009 | 30.70% | 69.30% | 150 |
| rest of world 2010–2012 | 9.50% | 90.50% | 190 |
| rest of world 2013–2015 | 4.20% | 95.80% | 237 |
| rest of world 2016–2018 | 19.10% | 80.90% | 157 |
| swine 1998–2015 | 54.2% | 45.8% | 48 |
| human 1998–2016 | 8.7% | 91.3% | 23 |
a All viruses are avian unless otherwise indicated. b The comparison was made only for isolates with glutamine or leucine at position 226 (H3 numbering). A small number of isolates, which had other amino acids at position 226, including methionine, were excluded from the percentage calculations.
Human H9N2 isolates.
| H9N2 Sequenced Human Viruses | Poultry Lineage |
|---|---|
| A/Shaoguan/447/1998 | Y280 |
| A/Shaoguan/408/1998 | Y280 |
| A/Shantou/239/1998 | Y280 |
| A/Hong Kong/1073/1999 | G1 |
| A/Hong Kong/1074/1999 | G1 |
| A/Guangzhou/333/1999 | Y280 |
| A/Nanchang/CH3/2000 | Y280 |
| A/Nanchang/D1/2000 | Y280 |
| A/Nanchang/D2/2000 | Y280 |
| A/Nanchang/CH2/2000 | Y280 |
| A/HK/2108/2003 | Y280 |
| A/Guangdong/W1/2004 | Y280 |
| A/Hong Kong/3239/2008 | Y280 |
| A/Hong Kong/69955/2008 | Y280 |
| A/Hong Kong/35820/2009 | G1 |
| A/Hong Kong/33982/2009 | G1 |
| A/Bangladesh/0994/2011 | G1 |
| A/Hong Kong/308/2014 | Y280 |
| A/Hunan/44557/2015 | Y280 |
| A/Zhongshan/201501/2015 | Y280 |
| A/Hunan/44558/2015 | Y280 |
| A/Beijing/1/2016 | Y280 |
| A/Guangdong/MZ058/2016 | Y280 |
| A/Beijing/1/2017 | Y280 |
H9N2 human serology studies.
| Country | Dates Sampled | Occupational Exposure | Percent Positiv (%) | General Exposure | Percent Positive (%) | HI Cutoff | Occupational Exposure | Percent Positive (%) | General Exposure | Percent Positive (%) | MN Cutoff | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China 1 | 1999 | 0/54 | 0 | 1/110 | 0.91 | 1600 | [ | |||||
| Vietnam 1 | 2001 | 1/200 | 0.5 | 0/200 | 0 | 1/40 | [ | |||||
| UnitedStates 2 | 2004 | 1/385 | 0.26 | 1/484 | 0.21 | 1/40 | [ | |||||
| China 1 | Apr. 2006–Feb. 2008 | 12/1060 | 1.1 | 0/407 | 0 | 1/160 | [ | |||||
| Iran 1 | Nov. 2006 | 48/127 | 37.7 | 0/25 | 0 | 1/20 | [ | |||||
| UnitedStates 2 | Mar. 2007–Apr. 2008 | 4/93 | 4.3 | 1/78 | 1.28 | 1/10 | [ | |||||
| China 1 | Mar. 2007–Jul. 2008 | 95/1890 | 5.03 | 4/301 | 1.33 | 1/20 | [ | |||||
| China 1 | Jan. 2008–Dec. 2010 | 103/840 | 12.47 | 47/1663 | 2.83 | 1/40 | 1/20 | [ | ||||
| Cambodia 3 | Apr. 2008–Oct. 2008 | 21/777 | 2.7 | 1/10 | [ | |||||||
| Thailand 3 | Apr. 2008–Oct. 2010 | 38/800 | 4.7 | 1/10 | [ | |||||||
| 12 Month | 21/768 | 2.7 | 1/10 | [ | ||||||||
| 24 Month | 40/784 | 5.1 | 1/10 | |||||||||
| Nigeria 2 | Dec. 2008–Jun. 2009 | 4/316 | 1.27 | 0/54 | 0 | 1/10 | [ | |||||
| United States 2 | 2009–2010 | 1/157 | 0.63 | 0/78 | 0 | [ | ||||||
| China 1 | 2009–2011 | 1912/14,896 | 12.8 | 1/40 | 453/14,896 | 3.04 | 1/40 | [ | ||||
| 489/13,453 | 3.6 | 159/13,453 | 1.18 | |||||||||
| Romania 2 | Feb. 2009–Jan. 2010 | 31/312 | 0.7 | 2/51 | 3.92 | 1/40 | 29/312 | 10.14 | 4/51 | 5.19 | 1/10 | [ |
| China 1 | Mar. 2009–Dec. 2012 | 37/2006 | 1.8 | 0/83 | 0 | 1/160 | 24/37 | 64.86 | 0 | [ | ||
| China 1 | May 2010 | 18/1039 | 1.73 | 1/40 | [ | |||||||
| India 1 | Jul. 2010–Dec. 2010 | 21/338 | 6.2 | 0/249 | 0 | 1/40 | 19/338 | 5.6 | 1/40 | [ | ||
| Iran 1 | Dec. 2010–Jul. 2011 | 3/182 | 1.6 | 0 | 0 | 1/20 | [ | |||||
| Pakistan 1 | 2010–2011 | 165/384 | 43.0 | 1/160 | [ | |||||||
| China 1 | Jan. 2011–Dec. 2013 | 51/600 | 8.5 | 11/600 | 1.8 | 1/40 | 51/600 | 8.5 | 11/600 | 1.8 | 1/40 | [ |
| China 1 | Mar. 2011 | 12/1741 | 0.7 | 1/40 | [ | |||||||
| China 1 | Dec. 2011–Feb. 2012 | 9/382 | 2.3 | 0/100 | 0 | 1/40 | 7/382 | 1.80 | 0/100 | 0 | 1/40 | [ |
| Iran 1 | Sep. 2012–Jan. 2013 | 12/100 | 12.0 | 2/100 | 2 | 1/40 | 17/100 | 17 | 3/100 | 3 | 1/40 | [ |
| China 1 | Oct. 2013–Jul. 2014 | 56/171 | 32.7 | 1/40 | [ | |||||||
| China 1 | Dec. 2013–Jan. 2014 | 50/546 | 9.2 | 5/264 | 1.89 | 1/40 | [ | |||||
| Vietnam 1 | 2013–2015 | 28/784 | 3.6 | 0 | 0 | 1/40 | [ | |||||
| Iran 1 | not reported | 98/300 | 32.6 | 8/300 | 2.5 | 1/40 | [ | |||||
| Iran 1 | not reported | 163/240 | 67.9 | 14/60 | 23.3 | 1/20 | [ | |||||
| Pakistan 1 | not reported | 209/465 | 45.0 | 0/25 | 0 | 1/160 | [ | |||||
| Egypt 1 | not reported | 0/60 | 0.0 | 1/40 | [ |
1 H9N2 is endemic in poultry in this country. 2 H9N2 is not endemic in poultry in this country. 3 H9N2 endemic status is unknown in this country.
Comparison of molecular markers of human adapted influenza strains.
| Gene Segment | Avian > Mammalian | Avian Isolates | Human Isolates | Activity |
|---|---|---|---|---|
| PB2 | K526R | 3.20% | 6.30% | increase polymerase activity, enhance virus replication |
| PB2 | A588V | 11.90% | 25% | higher polymerase activity, increased virulence mice |
| PB2 | E627K | 0.80% | 6.30% | associated with mammalian adaptation |
| PB2 | D701N | 0.05% | 6.30% | aerosol transmission guinea pigs |
Figure 1Phylogenetic tree of H9 hemagglutinin gene (Geneious 11.1.5). The four major poultry adapted lineages are color coded. Red-Korean lineage, Green-European lineage, Purple-G1, and Orange-Y280.